Business Context and Reporting Period
Company: Novartis AG
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Reporting Currency: Swiss Francs (CHF) with US Dollar ($) translations at CHF 1.40 = $1.00
Overview: Novartis is a global healthcare company organized into two primary divisions: Pharmaceuticals and Consumer Health. The 2002 period was marked by the divestiture of the Food & Beverage business, the acquisition of Lek Pharmaceuticals (Generics), and a strategic increase in the equity stake of Roche Holding AG.
Key Financial Metrics (2002)
| Metric | CHF (Millions) | USD (Millions) |
|---|---|---|
| Net Sales | 32,412 | 23,151 |
| Operating Income | 7,887 | 5,634 |
| Net Income | 7,313 | 5,225 |
| Operating Margin | 24.3% | 24.3% |
| Free Cash Flow (excl. major acquisitions) | 4,463 | 3,188 |
| Total Assets | 63,202 | 45,144 |
| Total Equity | 39,682 | 28,344 |
| Net Liquidity (Cash/Securities less Debt) | 9,786 | 6,990 |
| Total Financial Debt | 7,819 | 5,585 |
Material Changes vs. Prior Period (2001)
- Sales Growth: Net sales increased 2% in CHF (11% in local currencies) to CHF 32.4 billion. Growth was driven by a 10% volume increase and 1% price increase, partially offset by a 9% negative currency impact due to a stronger Swiss Franc.
- Profitability: Operating income rose 8% to CHF 7.9 billion. Net income increased 4% to CHF 7.3 billion. The operating margin improved by 1.3 percentage points to 24.3%.
- Divisional Performance:
- Pharmaceuticals: Sales grew 4% (CHF) / 13% (local). Key drivers included Diovan (CHF 2.6B), Gleevec/Glivec (CHF 953M), and Zometa (CHF 758M).
- Consumer Health: Sales remained flat in CHF terms but grew 7% in local currencies. The Generics unit saw a 15% sales increase driven by US launches.
- Acquisitions & Divestitures:
- Acquired 99% of Lek Pharmaceuticals (CHF 1.3B) to strengthen the Generics position in Eastern Europe.
- Divested the Food & Beverage business to Associated British Foods for CHF 402 million, realizing a gain of CHF 205 million.
- Increased investment in Roche Holding AG by CHF 2.9 billion, raising the voting share stake to 32.7%.
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Strategy: Novartis plans to change its reporting currency from Swiss Francs to US Dollars effective January 1, 2003. The company intends to maintain capital expenditure levels at 2002 levels (approx. 5.1% of sales) funded by internal resources.
- Dividend: The Board proposed a dividend of CHF 0.95 per share for 2002, to be voted on at the March 4, 2003 Annual General Meeting.
- Key Risks:
- Patent Expirations: Significant exposure to generic competition for key products including Neoral, Aredia, Sandostatin, Lotensin, Lamisil, and Voltaren.
- Regulatory & Pricing: Intense pressure on pricing in the US (Medicare reform), Europe (healthcare reforms), and Japan (biannual price cuts).
- Legal Proceedings: Ongoing litigation regarding generic versions of Augmentin (amoxicillin/potassium clavulanate) involving GlaxoSmithKline, and various product liability suits (e.g., PPA, Ritalin, Parlodel).
- Foreign Exchange: Significant exposure to USD, Euro, and Yen fluctuations, which negatively impacted reported sales growth in 2002.
- Unusual Items:
- Impairment charges of CHF 314 million related to biotechnology investments (Genetic Therapy, Systemix, Imutran) and CHF 80 million for pitavastatin marketing rights.
- Restructuring charges of CHF 84 million, primarily related to the reorganization of the Health Food & Slimming business into "Nutrition & Santé" and OTC restructuring.
Important Facts for Investor Verification
- Roche Investment Impact: Verify the accounting treatment and future earnings impact of the 32.7% stake in Roche Holding AG, which resulted in a pre-tax loss of CHF 180 million in 2002 due to amortization of purchase price allocations.
- Patent Cliff Timeline: Confirm the specific expiration dates and generic entry status for core revenue drivers: Neoral (2009+ formulation protection), Sandostatin (2003-2007 basic patent expiry), and Lotensin (2003-2004 US expiry).
- Legal Exposure: Monitor the outcome of the Augmentin patent litigation with GlaxoSmithKline, which could result in injunctions or significant damages.
- Accounting Transition: Review the upcoming transition to US Dollar reporting and the reconciliation differences between IAS and US GAAP (e.g., goodwill amortization ceased under US GAAP SFAS 142 in 2002).
- Divestiture of Nutrition & Santé: Track the progress of the planned sale of the reorganized Nutrition & Santé unit, which was separated to optimize business potential.